Elucidating the characteristics of human immune response against SARS-CoV-2 is of high
priority and relevant for determining vaccine strategies. We report the results of a follow-up …

More than a year after the start of the pandemic, COVID-19 remains a global health
emergency. Although the immune response against SARS-CoV-2 has been extensively …

Background The development of neutralizing antibodies (NAbs) against SARS-CoV-2,
following infection or vaccination, is likely to be critical for the development of sufficient …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes
coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and …

Background Convalescent plasma (CP) is a potentially important therapy for coronavirus
disease 2019 (COVID-19). However, knowledge regarding neutralizing antibody (NAb) titers …

As more and more patients recover from coronavirus disease 2019 (COVID-19) in the
coming weeks, convalescent plasma will become increasingly accessible as a treatment …

Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability
to fight off harmful microorganisms, including viruses such as Severe Acute Respiratory …

B cells specific for the SARS-CoV-2 S envelope glycoprotein spike were isolated from a
COVID-19-infected subject using a stabilized spike-derived ectodomain (S2P) twenty-one …

Summary SARS-CoV-2 neutralizing antibodies (NAbs) protect against COVID-19, making
them a focus of vaccine design. A safety concern regarding SARS-CoV-2 antibodies is …

The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019
(COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed …